Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetics of REC-994 as an Oral Treatment for Cerebral Cavernous Malformation (CCM)

Trial Profile

A Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetics of REC-994 as an Oral Treatment for Cerebral Cavernous Malformation (CCM)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Tempol (Primary)
  • Indications Central nervous system cavernous haemangioma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Recursion Pharmaceuticals
  • Most Recent Events

    • 04 Jan 2019 Status changed from planning to recruiting, according to a Recursion Pharmaceuticals media release.
    • 19 Jul 2018 New trial record
    • 10 Jul 2018 According to a Recursion Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase I clinical trial of REC-994 in the treatment of cerebral cavernous malformation (CCM). Company plans to initiate this trial later in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top